News|Articles|July 15, 2014

The Nexera MP UHPLC for LC/MS analysis in drug detection processes

Shimadzu?s Nexera MP UHPLC Front End system for LC/MS is perfect for LC/MS analysis conducted in pharmacokinetics and synthesis stages in drug detection processes.

The Nexera MP UHPLC for LC/MS analysis in drug detection processes

Shimadzu’s Nexera MP UHPLC Front End system for LC/MS is perfect for LC/MS analysis conducted in pharmacokinetics and synthesis stages in drug detection processes.

The SIL-30ACMP Multiplate Autosampler used in the Nexera MP is best suited for LC/MS analysis and has the industry-best micro-volume injection repeatability, the world’s highest injection speed and the lowest carryover. Combining the Nexera MP with Shimadzu’s LCMS-8030 Triple Quadrupole Mass Spectrometer or the LCMS-2020 Single Quadrupole Mass Spectrometer creates a system for quick analysis of multiple samples with high accuracy.

Additional outstanding features

  • Efficient sample preparation
    through excellent injection repeatability with micro volume injections streamlining the preparation process.

  • Two or more analyzers share one system
    supporting the reduction of energy consumption and operation costs.

  • Column oven setting to the MS position
    enabling achievement of ultra-high-speed, high-separation LC/MS analysis while maximizing the system’s separation performance.

The Nexera MP is controlled by Shimadzu’s LabSolutions software and major LC/MS workstations available from other companies.

For more details please visit www.shimadzu.eu


Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.